2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Workforce, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Paroxysmal Nocturnal Hemoglobinuria, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Metabolic Disorders, Iron Deficiency, Iron Overload, B Cell Lymphoma, Research, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4377 Intravenous iron practice patterns and infusion chair utilization at an academic medical center.

Ahmad Amir Kayali, MD, Daniel Valdes, PharmD, RPh2, Treasure Bright, PharmD3, Emily Wolf, MD4, Ewa Wysokinska, MD5, Candido E Rivera, MD6, Marwan Shaikh, MD7
1 Mayo Clinic Florida, Jacksonville, Florida, United States
2 Mayo Clinic Florida, Jacksonville, Florida, United States
3 Mayo Clinic Florida, Jacksonville, Florida, United States
4 Mayo Clinic Florida, Jacksonville, Florida, United States
5 Mayo Clinic Florida, Jacksonville, Florida, United States
6 Mayo Clinic Florida, Jacksonville, Florida, United States
7 Mayo Clinic Florida, Jacksonville, Florida, United States

Background:  Selection of an intravenous (IV) iron replacement agent for iron deficiency is often driven by provider or patient preference as well as institutional protocols, with published studies not showing superiority of one agent over another. IV Iron infusions require significant infusion time so the ideal preparation should give the highest efficacious iron dose in the least number of infusions to maximize benefit and minimize time commitment for the patient.  Iron dextran provides 1000 mg IV iron in one dose rather than a similar amount in multiple doses with other preparations. Combined with its lower cost and acceptable toxicity profile, these characteristics make iron dextran an attractive choice as the preferred agent. The aim of this project is to evaluate whether iron dextran will reduce the total number of visits for patients, and thus, save infusion chair time and improve infusion center access compared to using another IV iron preparation.

Methods: We conducted a retrospective review of all IV iron infusions at the Mayo Clinic Cancer Center Florida campus in 2023. We included all patients age at least 18 years old who received at least one dose of IV iron as an outpatient. The total milligram dose and total scheduled time for infusion visits for all IV iron doses, excluding iron dextran, was calculated. The number of equivalent iron dextran doses needed to achieve the same total milligram dose and then the time to give these doses was determined. The amount of time and cost saved by switching to iron dextran was then calculated. We also recorded the ordering provider to identify ordering preferences and patterns among various specialties.

Results: IV iron was ordered 1138 times for 1085 patients. The total number of IV iron infusion appointsments and doses given was 2786. One ferumoxytol infusion was excluded as a patient received it on the same day after reacting to iron sucrose. Of the remaing 2785 infusions, iron dextran accounted for 194 (7%) infusions, while the other iron preparations accounted for 2591 (93%) infusions. These preparations included iron sucrose, ferric gluconate, ferumoxytol, and ferric carboxymaltose. No patients received ferric derisomaltose as it not available at our institution. No patients who received iron dextran subsequently received a different IV iron within 2023. The total dose for the 2592 non-iron dextran infusions was 917,065 mg with the total scheduled infusion appointment time being 5121 hours. These numbers convert to 917 doses of iron dextran at 1000 mg each and 1834 hrs of time based on a 2-hour scheduled infusion appointment. The change to iron dextran would result in 1,675 less infusion appointments for patients and save 3287 hours of scheduled infusion time. This number is equivalent to one infusion chair remaining empty for almost 411 eight-hour working days and could lead to a drug cost savings of $1.15 million. Providers from 21 specialties ordered IV iron within 2023. The most common prescribed agent among hematology oncology providers was ferumoxytol, 246/510 (48%) unique IV iron orders, and among non-hematology oncology providers was iron sucrose, 256/628 (41%) unique IV iron orders. Among the specialties that showed at least a 67% preference for one IV iron formulation and had orders from two or more providers for ten or more patients, bariatric surgery preferred iron sucrose (21/26 patients, 81%), kidney/pancreatic transplant preferred iron sucrose (17/25 patients, 68%), and sleep medicine preferred ferric gluconate (98/101 patients, 97%).

Conclusion: IV iron infusions take a significant portion of available infusion chair time at our large cancer center.  Considering iron dextran as the preferred IV iron preparation would improve access, reduce scheduled infusion time, and decrease the time commitment from patients. The lower cost of iron dextran compared to other IV iron preparations also decreases the overall drug cost and makes it one of the preferred agents by insurance providers.

Marwan Shaikh, MD: No relevant conflicts of interest to declare.